Medications
Neurocognitive function decline but stable QOL in first year after temozolomide-based chemoradiotherapy
A secondary analysis of the NRG Oncology clinical trial NRG-RTOG 0424, which initially reported a 73.1% 3-year overall survival rate, shows a decline in neurocognitive function (NCF) for half of the trial participants with ...
Nov 25, 2019
0
1